S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The Next Nvidia? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The Next Nvidia? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The Next Nvidia? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Your Money is Not Safe (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The Next Nvidia? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
OTCMKTS:LXRP

Lexaria Bioscience (LXRP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free LXRP Stock Alerts
Compare
Today's Range
N/A
50-Day Range
$0.22
▼
$0.22
52-Week Range
N/A
Volume
2.15 million shs
Average Volume
608,350 shs
Market Capitalization
$20.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
LXRP stock logo

About Lexaria Bioscience Stock (OTCMKTS:LXRP)

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

LXRP Stock News Headlines

April 16, 2024 | msn.com
Lexaria gets ethics board okay for oral GLP-1 study
March 27, 2024 | theglobeandmail.com
Lexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Study
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 14, 2024 | msn.com
Lexaria appoints Nelson Cabatuan as CFO
March 11, 2024 | theglobeandmail.com
Lexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 Growth
February 16, 2024 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024 | msn.com
Why Lexaria Bioscience (LEXX) Shares Are Moving
January 16, 2024 | finance.yahoo.com
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 11, 2024 | finance.yahoo.com
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
November 30, 2023 | msn.com
LEXX: GLP-1s’ Sweet Opportunity
November 1, 2023 | finance.yahoo.com
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
October 18, 2023 | markets.businessinsider.com
Lexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical Trials
October 13, 2023 | finance.yahoo.com
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
August 5, 2023 | msn.com
Lexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector
August 2, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
July 29, 2023 | theglobeandmail.com
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study
July 28, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
July 28, 2023 | finance.yahoo.com
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
July 19, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
May 10, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting Results
May 10, 2023 | finance.yahoo.com
Lexaria Announces 2023 Annual Meeting Results
May 9, 2023 | theglobeandmail.com
Lexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine Study
May 9, 2023 | investorplace.com
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
May 8, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned
May 8, 2023 | finance.yahoo.com
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
April 25, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
See More Headlines
Receive LXRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Metal Mining
Sub-Industry
N/A
Current Symbol
OTCMKTS:LXRP
CUSIP
52886N208
CIK
1348362
Web
www.lexariabioscience.com
Phone
(250) 765-6424
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,090,000.00
Net Margins
-1,046.77%
Pretax Margin
N/A
Return on Equity
-157.62%
Return on Assets
-148.09%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.52
Quick Ratio
8.01

Sales & Book Value

Annual Sales
$380,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
89,587,000
Free Float
N/A
Market Cap
$20.15 million
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Christopher A. Bunka (Age 58)
    Chairman & CEO
    Comp: $300.8k
  • Mr. John M. Docherty (Age 51)
    Pres & Director
    Comp: $242.52k
  • Mr. Allan Spissinger C.A. (Age 51)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $121.66k
  • Vanessa Carle
    Head of Legal
  • Dr. Philip Ainslie
    Advisor & Consultant

Key Competitors

View All Competitors

LXRP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include Aurora Cannabis (ACBFF), Organigram (OGI), Cronos Group (CRON), Aphria (APHQF), CV Sciences (CVSI), Auxly Cannabis Group (CBWTF), iAnthus Capital (ITHUF), Alibaba Group (BABA) and GW Pharmaceuticals (GWPH).

How do I buy shares of Lexaria Bioscience?

Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:LXRP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
The “Perfect Storm” for Gold
Gold Safe Exchange
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The Next Nvidia?
InvestorPlace